Home » Stocks » BBI

Brickell Biotech, Inc. (BBI)

Stock Price: $0.943 USD 0.046 (5.07%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $0.912 -0.031 (-3.29%) May 7, 7:47 PM
Market Cap 63.11M
Revenue (ttm) 1.82M
Net Income (ttm) -20.91M
Shares Out 24.51M
EPS (ttm) -3.17
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $0.943
Previous Close $0.897
Change ($) 0.046
Change (%) 5.07%
Day's Open 0.940
Day's Range 0.910 - 0.950
Day's Volume 421,503
52-Week Range 0.466 - 2.610

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 days ago - Zacks Investment Research

BOULDER, Colo., April 29, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescrip...

1 week ago - GlobeNewsWire

Phase 3 Pivotal Cardigan II study exceeds 50% enrollment - - - Topline results for Phase 3 Pivotal Cardigan I and Cardigan II clinical studies expected in Q4 2021

1 week ago - GlobeNewsWire

Penny stocks on Robinhood are a big focus for Reddit traders in April The post 4 Reddit Penny Stocks To Buy On Robinhood For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Inf...

Other stocks mentioned: AIKI, KIQ, OGEN
2 weeks ago - PennyStocks

Biotech stocks are more popular than ever; here are 3 to watch under $5 The post Biotech Penny Stocks To Buy? 3 to Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other stocks mentioned: AIKI, BIOL
2 weeks ago - PennyStocks

Daily treatment with sofpironium bromide gel was generally well-tolerated over 48 weeks of treatment

2 weeks ago - GlobeNewsWire

BOULDER, Colo., April 16, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell” or the “Company”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differ...

3 weeks ago - GlobeNewsWire

Brickell (BBI) delivered earnings and revenue surprises of -87.50% and -97.30%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

Initiated U.S. pivotal Phase 3 clinical program (Cardigan I and II studies) evaluating sofpironium bromide gel, 15% for the treatment of primary axillary (underarm) hyperhidrosis

2 months ago - GlobeNewsWire

Webinar taking place on Friday, March 26th @ 10 am EDT Webinar taking place on Friday, March 26th @ 10 am EDT

2 months ago - GlobeNewsWire

Brickell (BBI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

BOULDER, Colo., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...

2 months ago - GlobeNewsWire

T opline results from the U.S. pivotal Phase 3 program anticipated in the fourth quarter of 2021 Sofpironium bromide gel, 5% (ECCLOCK ® ) recently launched in Japan by development partner, Kaken Pharmac...

5 months ago - GlobeNewsWire

Kaken plans to launch ECCLOCK ® for the treatment of primary axillary hyperhidrosis in Japan on November 26, 2020 - - - ECCLOCK ® placed on Japan's National Health Insurance (NHI) drug reimbursement pri...

5 months ago - GlobeNewsWire

BOULDER, Colo., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...

5 months ago - GlobeNewsWire

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q3 2020 Results - Earnings Call Transcript

5 months ago - Seeking Alpha

Recently completed capital raise expected to fully fund U.S. pivotal Phase 3 program, with topline results anticipated in Q4 2021 - - - Initiated the Cardigan I study, the first of two U.S. pivotal Phas...

5 months ago - GlobeNewsWire

BOULDER, Colo., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...

6 months ago - GlobeNewsWire

BOULDER, Colo., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescript...

6 months ago - GlobeNewsWire

Primary axillary h yperhidrosis is estimated to affect over 1 0 million p eople in the U.S .

7 months ago - GlobeNewsWire

Japan is the first country to approve sofpironium bromide with commercial launch expected later this year

7 months ago - GlobeNewsWire

BOULDER, Colo., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescr...

7 months ago - GlobeNewsWire

Advancement of the U.S. based program will be dependent upon results generated from AnGes’ ongoing and planned clinical studies in Japan Advancement of the U.S. based program will be dependent upon resu...

8 months ago - GlobeNewsWire

Claims directed to novel crystalline forms of sofpironium bromide

8 months ago - GlobeNewsWire

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q2 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Positive data from the Sofpironium Bromide Phase 3 pivotal study in Japan presented in Q2 2020 by development partner, Kaken Kaken to receive regulatory decision in Japan for sofpironium bromide gel ...

8 months ago - GlobeNewsWire

BOULDER, Colo., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescri...

9 months ago - GlobeNewsWire

BOULDER, Colo., June 17, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescri...

10 months ago - GlobeNewsWire

Data based on registration study in Japan of sofpironium bromide gel, 5% in patients with primary axillary hyperhidrosis

10 months ago - GlobeNewsWire

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks to short to...

Other stocks mentioned: DGLY, EYPT, HTBX, MNKD
11 months ago - Forbes

Brickell Biotech, Inc. (BBI) CEO Robert Brown on Q1 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Announces top-line results from 12-month, Phase 3, long-term safety study Announces top-line results from 12-month, Phase 3, long-term safety study

11 months ago - GlobeNewsWire

SFC (formerly known as Startup Funding Club – a UK a seed stage investor – has received £10 million from British Business Investments (the commercial subsidiary of the British Business Bank), to deploy ...

1 year ago - TechCrunch

Brickell Biotech, Inc. (BBI) CEO Rob Brown on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Shares of Brickell Biotech Inc. BBI, +60.86% were vaulted 61% higher on very heavy volume, putting them on track for the biggest one-day gain since the biopharmaceutical company went public 27 years ago...

1 year ago - Market Watch

Shares of thinly traded nano-cap biotech Brickell Biotech Inc (NASDAQ: BBI) are skyrocketing on above-average volume Thursday.

1 year ago - Benzinga

BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescri...

1 year ago - GlobeNewsWire

BOULDER, Colo., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. and its subsidiary (collectively, “Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing inno...

1 year ago - GlobeNewsWire

BOULDER, Colo., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescri...

1 year ago - GlobeNewsWire

About BBI

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Bou... [Read more...]

Industry
Biotechnology
Founded
2009
CEO
Robert Brown
Employees
13
Stock Exchange
NASDAQ
Ticker Symbol
BBI
Full Company Profile

Financial Performance

In 2020, BBI's revenue was $1.82 million, a decrease of -76.99% compared to the previous year's $7.92 million. Losses were -$20.91 million, -12.41% less than in 2019.

Financial Statements